Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study.
Charles N LandenRonald J BuckanovichMichael W SillRobert S MannelJoan L WalkerPaul A DiSilvestroCara A MathewsDavid G MutchMarcia L HernandezLainie P MartinErin BishopSarah E GillMary E GordinierRobert A BurgerCarol AghajanianJoyce F LiuKathleen M MooreMichael A BookmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Ruxolitinib 15 mg PO twice a day was well tolerated with acceptable toxicity in combination with paclitaxel/carboplatin chemotherapy. The primary end point of prolongation of PFS was achieved in the experimental arm, warranting further investigation.
Keyphrases